Outcomes of Chemotherapy plus Cetuximab as First-line Treatment in Patients with Metastatic, Recurrent, Unresectable Head and Neck Cancers: Real-life Data

Creative Commons License

Yazilitas D., ŞAHİNLİ H., Saylam G., İMAMOĞLU G. İ., Korkmaz M. H., Bayir O.

Journal of the College of Physicians and Surgeons Pakistan, cilt.33, sa.4, ss.469-473, 2023 (SCI-Expanded, Scopus)

Özet

Objective: To examine the treatment outcomes of the EXTREME regimen as the first-line therapy for recurrent/metastatic squamous cell carcinoma of the head and neck. Study Design: Observational study. Place and Duration of the Study: Department of Medical Oncology, Ankara Diskapi Yildirim Beyazit Training and Research Hospital, Turkiye, between January 2014 and December 2021. Methodology: A total of 60 patients with recurrent/metastatic head and neck cancers were treated with EXTREME regimen. Survival curves were estimated using the Kaplan-Meier method. Cox proportional hazards regression models were used to determine the factors associated with progression-free survival (PFS) and overall survival (OS). Results: Patients receiving cetuximab in combination with chemotherapy for metastatic or unresectable disease were obtained from patient files and electronic medical records. Majority of patients were male (78.3%). The median PFS of patients was 7 months. The median survival of the patients was 9.06 months. During follow-up, 55 patients (91.7%) relapsed, and 51 patients (85%) died. The median survival of patients with eastern cooperative oncology group (ECOG) performance status 0, 1, and 2 was 16, 9, and 4 months, respectively. And the survival of patients was found significantly lower with lower ECOG performance scores. Conclusion: OS was determined as 9.06 months. ECOG performance score had an important effect on the survival.